[Efficacy and safety of antiCD20 monoclonal antibody divozilimab during 48-week treatment of multiple sclerosis patients in randomized double-blind placebo-controlled clinical trial BCD-132-4/MIRANTIBUS].
A N BoykoValentina M AlifirovaI G LukashevichZoya A GoncharovaI V GreshnovaL G ZaslavskyS V KotovN A MalkovaG N MishinYe V ParshinaI Ye PoverennovaL N PrakhovaStella SivertsevaI V SmaginaN A TotolyanYu V TrinitatskyT N TrushnikovaF A KhabirovZh Yu ChefranovaS G ShchurV A DudinD V PokhabovD D BolsunAnna V EremeevaYulia N LinkovaArina V Zinkina-OrikhanPublished in: Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova (2023)
The results of the clinical study indicate the high efficacy and safety of DIV in comparison with TRF.